Literature DB >> 35527487

[Dihydromyricetin reduces lipid accumulation in LO2 cells via AMPK/mTOR-mediated lipophagy pathway and inhibits HepG2 cell proliferation in vitro].

X Liao1, Y Hao1, M Wu1, H Liu2, L Jiang2, Z Ye1, W Liao1, H Deng1.   

Abstract

OBJECTIVE: To explore the mechanism underlying the hepatoprotective effect of dihydromyricetin (DMY) against lipid accumulation in light of the lipophagy pathway and the inhibitory effect of DMY on HepG2 cell proliferation.
METHODS: LO2 cells were cultured in the presence of 10% FBS for 24 h and treated with 100 μg/mL DMY, or exposed to 50% FBS for 24 h followed by treatment with 50, 100, or 200 μg/mL DMY; the cells in recovery group were cultured in 50% FBS for 24 h and then in 10% FBS for another 24 h. Oil red O staining was used to observe the accumulation of lipid droplets in the cells, and the levels of TC, TG, and LDL and activities of AST, ALT and LDH were measured. The expression of LC3 protein was detected using Western blotting. AO staining and transmission electron microscopy were used to determine the numbers of autophagolysosomes and autophagosomes, respectively. The formation of autophagosomes was observed with MDC staining, and the mRNA expression levels of LC3, ATG7, AMPK, mTOR, p62 and Beclin1 were determined with q-PCR. Flow cytometry was performed to analyze the effect of 50, 100, and 200 μg/mL DMY on cell cycle and apoptosis of HepG2 cells; DNA integrity in the treated cells was examined with cell DNA fragmentation test.
RESULTS: DMY treatment and pretreatment obviously inhibited lipid accumulation and reduced the levels of TC, TG, LDL and enzyme activities of AST, ALT and LDH in LO2 cells (P < 0.05). In routinely cultured LO2 cells, DMY significantly promoted the formation of autophagosomes and autophagolysosomes and upregulated the expression of LC3 protein. DMY obviously attenuated high FBS-induced inhibition of autophagosome formation in LO2 cells, up- regulated the mRNA levels of LC3, ATG7, Beclin1 and AMPK, and downregulated p62 and mTOR mRNA levels (P < 0.05 or 0.01). In HepG2 cells, DMY caused obvious cell cycle arrest, inhibited cell proliferation, and induced late apoptosis and DNA fragmentation.
CONCLUSION: DMY reduces lipid accumulation in LO2 cells by regulating the AMPK/ mTOR-mediated lipophagy pathway and inhibits the proliferation of HepG2 by causing cell cycle arrest and promoting apoptosis.

Entities:  

Keywords:  AMPK/mTOR; dihydromyricetin; lipophagy; nonalcoholic fatty liver disease; proliferation inhibition

Mesh:

Substances:

Year:  2022        PMID: 35527487      PMCID: PMC9085583          DOI: 10.12122/j.issn.1673-4254.2022.04.07

Source DB:  PubMed          Journal:  Nan Fang Yi Ke Da Xue Xue Bao        ISSN: 1673-4254


  37 in total

1.  Homeostatic levels of p62 control cytoplasmic inclusion body formation in autophagy-deficient mice.

Authors:  Masaaki Komatsu; Satoshi Waguri; Masato Koike; Yu-Shin Sou; Takashi Ueno; Taichi Hara; Noboru Mizushima; Jun-Ichi Iwata; Junji Ezaki; Shigeo Murata; Jun Hamazaki; Yasumasa Nishito; Shun-Ichiro Iemura; Tohru Natsume; Toru Yanagawa; Junya Uwayama; Eiji Warabi; Hiroshi Yoshida; Tetsuro Ishii; Akira Kobayashi; Masayuki Yamamoto; Zhenyu Yue; Yasuo Uchiyama; Eiki Kominami; Keiji Tanaka
Journal:  Cell       Date:  2007-12-14       Impact factor: 41.582

Review 2.  Endoplasmic reticulum stress signalling and the pathogenesis of non-alcoholic fatty liver disease.

Authors:  Cynthia Lebeaupin; Deborah Vallée; Younis Hazari; Claudio Hetz; Eric Chevet; Béatrice Bailly-Maitre
Journal:  J Hepatol       Date:  2018-06-27       Impact factor: 25.083

Review 3.  Nonalcoholic fatty liver disease: from steatosis to cirrhosis.

Authors:  Geoffrey C Farrell; Claire Z Larter
Journal:  Hepatology       Date:  2006-02       Impact factor: 17.425

4.  Dihydromyricetin modulates p62 and autophagy crosstalk with the Keap-1/Nrf2 pathway to alleviate ethanol-induced hepatic injury.

Authors:  Ping Qiu; Yu Dong; Bo Li; Xian-Jie Kang; Chao Gu; Tao Zhu; Yun-Yun Luo; Min-Xia Pang; Wei-Feng Du; Wei-Hong Ge
Journal:  Toxicol Lett       Date:  2017-04-15       Impact factor: 4.372

Review 5.  Nonalcoholic Fatty Liver Disease as a Nexus of Metabolic and Hepatic Diseases.

Authors:  Varman T Samuel; Gerald I Shulman
Journal:  Cell Metab       Date:  2017-08-31       Impact factor: 27.287

Review 6.  Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes.

Authors:  Zobair M Younossi; Aaron B Koenig; Dinan Abdelatif; Yousef Fazel; Linda Henry; Mark Wymer
Journal:  Hepatology       Date:  2016-02-22       Impact factor: 17.425

7.  Modulation of SIRT1-mediated signaling cascades in the liver contributes to the amelioration of nonalcoholic steatohepatitis in high fat fed middle-aged LDL receptor knockout mice by dihydromyricetin.

Authors:  Yi Zeng; Yi Qiao Hua; Wei Wang; Hua Zhang; Xiao Le Xu
Journal:  Biochem Pharmacol       Date:  2020-03-23       Impact factor: 5.858

Review 8.  Global epidemiology of NAFLD-related HCC: trends, predictions, risk factors and prevention.

Authors:  Daniel Q Huang; Hashem B El-Serag; Rohit Loomba
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2020-12-21       Impact factor: 46.802

Review 9.  Recent Update on the Pharmacological Effects and Mechanisms of Dihydromyricetin.

Authors:  Jingyao Zhang; Yun Chen; Huiqin Luo; Linlin Sun; Mengting Xu; Jin Yu; Qigang Zhou; Guoliang Meng; Shengju Yang
Journal:  Front Pharmacol       Date:  2018-10-25       Impact factor: 5.810

Review 10.  The Upstream Pathway of mTOR-Mediated Autophagy in Liver Diseases.

Authors:  Haojie Wang; Yumei Liu; Dongmei Wang; Yaolu Xu; Ruiqi Dong; Yuxiang Yang; Qiongxia Lv; Xiaoguang Chen; Ziqiang Zhang
Journal:  Cells       Date:  2019-12-09       Impact factor: 6.600

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.